In this edition
- A year in review
- Shutdown period
- What could be lurking in your holiday feast?
- Join a network of diagnostics professionals
A Year in Review2024 was a year defined by bold changes to our products, our service, and who we are as a company. We benefit from a consistent culture of questioning the norm and considering radical change if it benefits our customers, users, and patient outcomes. AusDiagnostics & R-Biopharm: Partners in Molecular Diagnostics You may recall our announcement last year when AusDiagnostics was acquired by R-Biopharm AG, a global leader in diagnostics solutions. Since the acquisition, we have worked closely with the global R-Biopharm team to synergise our operational efficiency and distribute our technologies to new markets. This month, we announced the next stage of our integration with R-Biopharm AG. AusDiagnostics will transition to operate under the R-Biopharm brand, delivering the same quality products under a globally recognised identity.
Expanding our OEM capabilities One of our proudest achievements of the year was the HighPlex Ascend, the next generation of low to medium-throughput MT-PCR processors. Incorporating our years of experience in automation and post-market surveillance, our team delivered what is now our flagship OEM solution for molecular diagnostics automation.
Solutions for neglected tropical diseases This year, we announced our new Vector-Borne Diseases portfolio of molecular diagnostics. Intended to provide support to clinicians contending with neglected tropical diseases, the panels represent the fulfillment of our Tailored Panels Initiative, in which we lend our expertise and resources to partners with localised health knowledge. These collaborations promise to uplift the standard of healthcare by providing tailored diagnostics specific to local needs.
Supporting the Mpox global health emergency The AusDiagnostics team has been closely monitoring the spread of mpox this year as the World Health Organization (WHO) declared a public health emergency of international concern (PHEIC) in response to a worrying increase in transmission. In support of clinicians worldwide, we developed a monkeypox virus assay for the differential diagnosis of lesion-causing pathogens. Our relationship with our customers is a collaborative partnership, and we believe that this means it is our responsibility to support our customers with up to date diagnostics solutions in response to our changing healthcare landscape.
|
Shutdown periodAs we near our end of year period, please take note of the dates of our shutdown period.
For emergency service support during the shutdown period, kindly contact support@ausdx.com or the phone numbers below.
For support with antigen rapid tests during the shutdown, kindly visit www.ausdiagnostics.care or call +61 2 9698 8030 extension 1. |
What could be lurking in your holiday feast?The holiday season is a time for sharing. Amongst the atmosphere of merriment and indulgence, you may be sharing some unwanted gifts in your holiday feast. Food-borne gastroenteritis hospitalises approximately 50,000 Australians each year.1 Prepare your community for food-borne illness with AusDiagnostics Gastrointestinal panels that include the most common bacterial pathogens, shiga toxins, obligatory pathogenic parasites, and enteric viruses.
|
Join a network of diagnostics professionalsOur social media community is a unique blend of professionals from clinical and non-clinical backgrounds. Following AusDiagnostics on social media is the perfect way to connect with an up-to-date network of peers to discuss the latest updates in the diagnostics world.
In case you missed it, here is a taste of our recent updates from Linkedin.
|
| Be the first to receive AusDiagnostics updates: |
Join the conversation:
    ↑ Back to top |
